These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19106147)

  • 21. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
    Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
    Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
    [TBL] [Abstract][Full Text] [Related]  

  • 22. c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
    Fu L; Lin YD; Elrod HA; Yue P; Oh Y; Li B; Tao H; Chen GZ; Shin DM; Khuri FR; Sun SY
    Mol Cancer; 2010 Dec; 9():315. PubMed ID: 21172010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
    BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation.
    MacFarlane M; Cohen GM; Dickens M
    Biochem J; 2000 May; 348 Pt 1(Pt 1):93-101. PubMed ID: 10794718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.
    Wahl K; Siegemund M; Lehner F; Vondran F; Nüssler A; Länger F; Krech T; Kontermann R; Manns MP; Schulze-Osthoff K; Pfizenmaier K; Bantel H
    Hepatology; 2013 Feb; 57(2):625-36. PubMed ID: 22991197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TRAIL-induced apoptosis of hepatocellular carcinoma cells is augmented by targeted therapies.
    Koehler BC; Urbanik T; Vick B; Boger RJ; Heeger S; Galle PR; Schuchmann M; Schulze-Bergkamen H
    World J Gastroenterol; 2009 Dec; 15(47):5924-35. PubMed ID: 20014456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
    Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
    Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cisplatin sensitizes human hepatocellular carcinoma cells, but not hepatocytes and mesenchymal stem cells, to TRAIL within a therapeutic window partially depending on the upregulation of DR5.
    Zhang B; Shan H; Li D; Li ZR; Zhu KS; Jiang ZB; Huang MS
    Oncol Rep; 2011 Feb; 25(2):461-8. PubMed ID: 21152876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The histone deacetylase inhibitor suberoylanilide hydroxamic acid sensitises human hepatocellular carcinoma cells to TRAIL-induced apoptosis by TRAIL-DISC activation.
    Carlisi D; Lauricella M; D'Anneo A; Emanuele S; Angileri L; Di Fazio P; Santulli A; Vento R; Tesoriere G
    Eur J Cancer; 2009 Sep; 45(13):2425-38. PubMed ID: 19643600
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1.
    Azijli K; Yuvaraj S; van Roosmalen I; Flach K; Giovannetti E; Peters GJ; de Jong S; Kruyt FA
    Apoptosis; 2013 Jul; 18(7):851-60. PubMed ID: 23456625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glycogen synthase kinase-3 inhibitors augment TRAIL-induced apoptotic death in human hepatoma cells.
    Beurel E; Blivet-Van Eggelpoël MJ; Kornprobst M; Moritz S; Delelo R; Paye F; Housset C; Desbois-Mouthon C
    Biochem Pharmacol; 2009 Jan; 77(1):54-65. PubMed ID: 18938143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A green tea polyphenol, epigalocatechin-3-gallate, induces apoptosis of human hepatocellular carcinoma, possibly through inhibition of Bcl-2 family proteins.
    Nishikawa T; Nakajima T; Moriguchi M; Jo M; Sekoguchi S; Ishii M; Takashima H; Katagishi T; Kimura H; Minami M; Itoh Y; Kagawa K; Okanoue T
    J Hepatol; 2006 Jun; 44(6):1074-82. PubMed ID: 16481065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C-jun N-terminal kinase activation is required for apoptotic cell death induced by TNF-related apoptosis-inducing ligand plus DNA-damaging agents in sarcoma cell lines.
    Mikami T; Koyama T; Koyama T; Imakiire A; Yamamoto K; Furuhata M; Toyota H; Mizuguchi J
    Anticancer Res; 2006; 26(2A):1153-60. PubMed ID: 16619517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lithium enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells.
    Lan Y; Liu X; Zhang R; Wang K; Wang Y; Hua ZC
    Biometals; 2013 Apr; 26(2):241-54. PubMed ID: 23378009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation.
    Carlisi D; D'Anneo A; Angileri L; Lauricella M; Emanuele S; Santulli A; Vento R; Tesoriere G
    J Cell Physiol; 2011 Jun; 226(6):1632-41. PubMed ID: 21413021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations.
    Meurette O; Lefeuvre-Orfila L; Rebillard A; Lagadic-Gossmann D; Dimanche-Boitrel MT
    Clin Cancer Res; 2005 Apr; 11(8):3075-83. PubMed ID: 15837763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Licochalcone B induces DNA damage, cell cycle arrest, apoptosis, and enhances TRAIL sensitivity in hepatocellular carcinoma cells.
    Zhang YY; Feng PP; Wang HF; Zhang H; Liang T; Hao XS; Wang FZ; Fei HR
    Chem Biol Interact; 2022 Sep; 365():110076. PubMed ID: 35948134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
    Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents.
    Sánchez-Pérez T; Ortiz-Ferrón G; López-Rivas A
    Cell Death Differ; 2010 May; 17(5):883-94. PubMed ID: 19942932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
    Ahmad M; Shi Y
    Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.